RCS - Sareum Holdings PLC - Sareum notes publication of SRA737 clinical data

Sareum HoldingsAnnouncement

21/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221121:nRSU9860Ga&default-theme=true

RNS Number : 9860G  Sareum Holdings PLC  21 November 2022

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum notes publication of Phase I/2 clinical data on SRA737 as a combination
treatment for advanced cancers in Clinical Cancer Research

·    First peer-reviewed data of Phase I/2 Trial of Oral SRA737 (a Chk1
Inhibitor) in Combination with Low-Dose Gemcitabine in Patients with Advanced
Cancer

Cambridge, UK, 21 November 2022 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, notes the publication of data from a Phase I/2
trial of SRA737, a clinical-stage oral, selective small molecule Checkpoint
kinase 1 (Chk1) inhibitor, in combination with widely used chemotherapeutic
agent gemcitabine, in the November 15 edition of Clinical Cancer Research.

The paper can be accessed here
(https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-2074/710713/A-Phase-I-II-Trial-of-Oral-SRA737-a-Chk1-Inhibitor)
.

Sareum retains a 27.5% economic interest in SRA737 arising from its
collaboration in the discovery and early development of the molecule.
Following the October 2022 notification that Sierra Oncology will return the
rights, Sareum is evaluating potential development opportunities alongside
co-development partner the CRT Pioneer Fund LP ("CPF").

 

This is the first peer-reviewed publication of clinical data on trials
conducted using a Chk1 inhibitor in combination with a novel, lower dose of
gemcitabine compared to standard of care, and the first clinical report of
SRA737 used as a combination treatment. This dataset was initially published
at the American Society of Clinical Oncology (ASCO) meeting in 2019.

The objectives of the trial were to establish the safety profile, recommended
Phase 2 dose, pharmacokinetics profile, and clinical activity of SRA737.

Treatment of patients with SRA737 in combination with low-dose gemcitabine was
found to be well tolerated and resulted in lower myelotoxicity compared to
standard doses of gemcitabine alone or in combination with other Chk1
inhibitors. Tumour responses were observed in anogenital and other solid
tumours.

The objective response rate (ORR) in anogenital cancer was 25%. Partial tumour
responses were observed in anogenital cancer, cervical cancer, high-grade
serous ovarian cancer, rectal cancer, and small cell lung cancer. Toxicities
observed were primarily mild to moderate, and rarely led to treatment
discontinuation.

 

Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are pleased
to see the data from the Phase I/2 trial of SRA737 published in the
peer-reviewed journal Clinical Cancer Research, demonstrating SRA737's
anti-cancer activity in multiple indications.

"As we assess opportunities to further develop this asset, subject to
discussions with our partners, this is an encouraging development which
reinforces our confidence in the potential of SRA737."

- Ends -

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Oliver Duckworth                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   0203 709 5700

 

About SRA737

SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that
targets cancer cell replication and DNA damage repair mechanisms, was
discovered and initially developed by scientists at The Institute of Cancer
Research in collaboration with Sareum, with funding from Sareum and Cancer
Research UK.

 

The CRT Pioneer Fund acquired worldwide commercial rights to the programme in
2013 as part of a co-development agreement with Sareum. SRA737 was licensed by
CPF to Sierra Oncology in 2016. Sierra progressed SRA737 through Phase 1/2
clinical development and, at the 2019 ASCO Annual meeting, reported positive
preliminary efficacy and safety data from two clinical trials evaluating
SRA737 as a monotherapy and in combination with chemotherapy.

Sareum was informed by Sierra Oncology (now a subsidiary of GSK plc "GSK") in
October 2022 that Sierra intends to return the rights for SRA737 to the CRT
Pioneer Fund LP. Sareum will discuss actively with CPF the potential options
for future development opportunities for SRA737 and evaluate its next steps
accordingly.

Sierra was acquired by GSK in July 2022.

About Sareum

Sareum Holdings (AIM:SAR) is a biotechnology company developing next
generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC 1801, simultaneously inhibits TYK2 and JAK1. SDC1801
is a potential treatment for a range of autoimmune diseases. Sareum is also
developing SDC1802, a TYK2/JAK1 inhibitor with a potential application for
cancer immunotherapy.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit the
Company's website at www.sareum.com (http://www.sareum.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPGCAGUPPPUU